PTC Therapeutics (PTCT) PT Raised to $37 at Goldman Sachs, 'stock in an increasingly precarious position ahead of higher risk'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DVLT

Go back to PTC Therapeutics (PTCT) PT Raised to $37 at Goldman Sachs, 'stock in an increasingly precarious position ahead of higher risk'

PTC Therapeutics (PTCT) PT Raised to $70 at Citi, 'Post-data, we increased our sepiapterin POS to 90%'

May 17, 2023 2:43 PM EDT

Citi analyst David Lebowitz raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $70.00 (from $67.00) while maintaining a Buy rating.

The analyst comments "Today, PTCT held a call to discuss positive sepiapterin (PTC923) pivotal data in phenylketonuria (PKU) and competitive dynamics. Given the deeper... More

PTC Therapeutics (PTCT) Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients

May 17, 2023 7:02 AM EDT

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical trial of sepiapterin in adult and pediatric patients with phenylketonuria (PKU).

"The positive results from the APHENITY trial bring us one step... More